Tibor Keler
Net Worth

Last updated:

What is Tibor Keler net worth?

The estimated net worth of Dr. Tibor Keler is at least $10,597,663 as of 7 Dec 2022. He owns shares worth $151,407 as insider, has earned $622,606 from insider trading and has received compensation worth at least $9,823,650 in Celldex Therapeutics, Inc..

What is the salary of Tibor Keler?

Dr. Tibor Keler salary is $654,910 per year as Founder, Chief Scientific Officer & Executive Vice President in Celldex Therapeutics, Inc..

How old is Tibor Keler?

Dr. Tibor Keler is 66 years old, born in 1959.

What stocks does Tibor Keler currently own?

As insider, Dr. Tibor Keler owns shares in one company:

Company Title Shares Price per share Total value
Celldex Therapeutics, Inc. (CLDX) Founder, Chief Scientific Officer & Executive Vice President 7,357 $20.58 $151,407

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX logo
CLDX
Celldex Therapeutics, Inc.
$20.58

Tibor Keler insider trading

Celldex Therapeutics, Inc.

Dr. Tibor Keler has made only one insider trade between 2010-2022, according to the Form 4 filled with the SEC.

As of 7 Dec 2022 he still owns at least 7,357 units of CLDX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock, par value $0.001 per share 16,860 $2.78 $46,871
Option
Incentive Stock Option (right to buy) 16,860 $2.78 $46,871
Sale
Common Stock, par value $0.001 per share 16,860 $36.93 $622,606
Purchase
Common Stock, par value $0.001 per share 5,000 $2.99 $14,955
Purchase
Common Stock, par value $0.001 per share 16,500 $0.59 $9,785
Purchase
Common Stock, par value $0.001 per share 3,000 $3.32 $9,960
Purchase
Common Stock 5,000 $2.5 $12,520
Purchase
Common Stock 5,000 $3.52 $17,600

Celldex Therapeutics key executives

Celldex Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Margo Heath-Chiozzi M.D. (68) Senior Vice President of Regulatory Affairs
  • Dr. Tibor Keler (66) Founder, Chief Scientific Officer & Executive Vice President
  • Mr. Anthony S. Marucci M.B.A. (63) Founder, Pres, Chief Executive Officer & Director
  • Mr. Sam Martin (54) Senior Vice President, Chief Financial Officer, Sec. & Treasurer
  • Ms. Elizabeth Crowley (53) Chief Product Devel. Officer & Senior Vice President